Syncom Formulation (India) Ltd. (IN:SYNCOMF)
:SYNCOMF
Want to see IN:SYNCOMF full AI Analyst Report?
SYNCOMF Stock Chart & Stats
₹13.98
-₹0.26(-1.33%)
At close: 4:00 PM EST
₹13.98
-₹0.26(-1.33%)
Day’s Range― - ―
52-Week Range₹10.21 - ₹23.46
Previous CloseN/A
Volume2.15M
Average Volume (3M)249.72K
Market Cap
₹14.68B
Enterprise Value₹14.66B
Total Cash (Recent Filing)₹1.45B
Total Debt (Recent Filing)₹6.97M
Price to Earnings (P/E)19.1
Beta1.61
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding940,000,000
10 Day Avg. Volume232,913
30 Day Avg. Volume249,719
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.34
Price to Sales (P/S)1.99
P/FCF Ratio21.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
De-risked, Very Low‑leverage Balance SheetA dramatic reduction in debt and equity expansion materially improves solvency and financial optionality. Low leverage lowers refinancing and interest risk, supports working capital and capex, and gives management flexibility for strategic investments or opportunistic M&A over the medium term.
Improved Profitability / Higher Net MarginA sustained net margin around 15.6% demonstrates improved earnings power and operational control relative to prior years. Consistent operating margins enable reinvestment in R&D and sales, support cash generation, and make profits less sensitive to moderate top‑line swings over the next several quarters.
Rebounded Operating Cash Flow And Strong Free Cash FlowThe return to meaningful operating and free cash flow shows the business can convert earnings into cash, supporting capex, debt reduction and potential shareholder returns. Strong FY2026 cash flow improves financial resilience and funding capacity for growth initiatives over coming months.
Bears Say
Top‑line Decline In FY2026A 5% revenue drop after prior expansion suggests demand weakness or loss of momentum. Without clear new product launches or channel gains, top‑line contraction can limit the durability of recent profit improvements and constrains ability to achieve scale economies over the next 2–6 months.
Sharp Gross Margin CompressionA near 7 percentage‑point gross margin decline implies adverse mix, pricing pressure or higher input costs. If structural, this erodes operating leverage and forces management to either restore pricing, shift mix, or cut costs—actions that take multiple quarters to implement and may reduce growth runway.
Historically Uneven Cash ConversionDespite a strong FY2026, prior years showed negative OCF/FCF and inconsistent conversion of profits to cash. That variability increases execution risk for capital allocation and makes recurring dividends or sustained buybacks harder to commit to until cash conversion proves consistently reliable.
Syncom Formulation (India) Ltd. News
SYNCOMF FAQ
What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?
Syncom Formulation (India) Ltd. lowest stock price was ₹10.21 and its highest was ₹23.46 in the past 12 months.
What is Syncom Formulation (India) Ltd.’s market cap?
Syncom Formulation (India) Ltd.’s market cap is ₹14.68B.
When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?
Syncom Formulation (India) Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 72 days.
How were Syncom Formulation (India) Ltd.’s earnings last quarter?
Syncom Formulation (India) Ltd. released its earnings results on May 22, 2026. The company reported ₹0.27 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.27.
Is Syncom Formulation (India) Ltd. overvalued?
According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued.
Does Syncom Formulation (India) Ltd. pay dividends?
Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.03 which represents an annual dividend yield of N/A. See more information on Syncom Formulation (India) Ltd. dividends here
What is Syncom Formulation (India) Ltd.’s EPS estimate?
Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Syncom Formulation (India) Ltd. have?
Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.
What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?
Syncom Formulation (India) Ltd. reported an EPS of ₹0.27 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.42%.
Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?
Currently, no hedge funds are holding shares in IN:SYNCOMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Syncom Formulation (India) Ltd.
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.
Technical Analysis
GRP Ltd
―
Knowledge Marine & Engineering Works Limited
―
Media Matrix Worldwide Limited
―
Updater Services Limited
―
Uniparts India Ltd.
―